Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

THC

Here's What Analysts Think of THC.

This afternoon we watched Tenet Healthcare drop -10.0% to a price of $124.91 per share. The Large-Cap Medical Care Facility company is now trading -29.17% below its average target price of $176.36. Analysts have set target prices ranging from $140.0 to $217.0 per share for Tenet Healthcare, and have given the stock an average rating of buy.

The stock has an average amount of shares sold short at 4.1%, and a short ratio of 2.94. The company's insiders own 1.57% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 101.7% of Tenet Healthcare's shares being owned by this investor type.

Institutions Invested in Tenet Healthcare

Date Reported Holder Percentage Shares Value
2024-12-31 Blackrock Inc. 11% 10,552,615 $1,318,127,178
2024-12-31 Vanguard Group Inc 11% 10,074,795 $1,258,442,680
2024-09-30 FMR, LLC 8% 7,700,693 $961,893,590
2024-09-30 Price (T.Rowe) Associates Inc 8% 7,468,372 $932,874,373
2024-09-30 Invesco Ltd. 5% 5,042,292 $629,832,712
2024-12-31 Pacer Advisors, Inc. 4% 3,832,530 $478,721,336
2024-09-30 State Street Corporation 3% 2,907,644 $363,193,822
2024-09-30 Glenview Capital Management, Llc 3% 2,658,791 $332,109,593
2024-09-30 Geode Capital Management, LLC 2% 2,044,667 $255,399,362
2024-09-30 Arrowstreet Capital, Limited Partnership 2% 1,815,484 $226,772,113

Besides an analyst consensus of strong upside potential, other market factors point to there being positive market sentiment on Tenet Healthcare.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS